Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
AIDS Dementia Complex D015526 4 associated lipids
Neoplasms, Germ Cell and Embryonal D009373 4 associated lipids
Burns, Inhalation D002059 4 associated lipids
Shock, Traumatic D012774 4 associated lipids
Hypertrophy, Right Ventricular D017380 4 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Brain Injuries D001930 4 associated lipids
Milk Hypersensitivity D016269 4 associated lipids
Thrombocytosis D013922 4 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Peyman JA et al. HLA-DR genes are silenced in human trophoblasts and stimulation of signal transduction pathways does not circumvent interferon-gamma unresponsiveness. 1992 Transplant. Proc. pmid:1533073
Kecskemeti V and Balogh I Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021. 1995 Transplant. Proc. pmid:7482928
Yin M et al. Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury. 1995 Transplant. Proc. pmid:7482939
Spiegel HU et al. Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. 1995 Transplant. Proc. pmid:7482955
Borobia FG et al. Platelet-activating factor antagonist BN52021 improves survival in normothermic liver ischemia in rats. 1993 Transplant. Proc. pmid:8356661
Iwamoto H et al. Beneficial effect of machine perfusion preservation on liver transplantation from non-heart-beating donors. 2000 Transplant. Proc. pmid:11119873
Da Costa M et al. Prolongation of rat heart allograft survival using low-dose cyclosporine and PAF antagonist WEB 2170. 1990 Transplant. Proc. pmid:2389490
Bergmann R et al. Effects of a PAF-antagonist (WEB 2086) on hyperacute xenogeneic rejection in ex vivo perfused kidneys. 1990 Transplant. Proc. pmid:2389511
Immunomodulation: other approaches. 1988 Transplant. Proc. pmid:3347955
Renkonen R et al. Second messenger pathways in lymphocyte binding and penetration through graft vascular endothelium. 1991 Transplant. Proc. pmid:1846709
Pignol B et al. Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection. 1988 Transplant. Proc. pmid:3259039
Takada Y et al. Platelet activating factor antagonist has a protective effect on preservation/reperfusion injury of the graft in pig liver transplantation. 1995 Transplant. Proc. pmid:7879169
Yin M et al. Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury. 1995 Transplant. Proc. pmid:7879180
Hirt SW et al. Antagonisation of platelet activating factor--a new therapeutic concept for improvement of organ quality in lung preservation. 1992 Transpl. Int. pmid:14621825
Torras J et al. Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model. 1993 Transpl. Int. pmid:8347271
Räisänen A et al. Effect of platelet-activating factor (PAF) receptor blockers on smooth muscle cell replication in vitro and allograft arteriosclerosis in vivo. 1993 Transpl. Int. pmid:8216700
Shukla SD et al. Response to platelet-activating factor in human platelets stored and aged in plasma. Decrease in aggregation, phosphoinositide turnover, and receptor affinity. 1989 Jul-Aug Transfusion pmid:2546298
Guerrant RL et al. Diarrhea, demography and cell signaling: lessons from microbial toxins. 1997 Trans. Am. Clin. Climatol. Assoc. pmid:9108674
Melo RC et al. Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils. 2005 Traffic pmid:16138901
Tai H et al. TMVA, a snake C-type lectin-like protein from Trimeresurus mucrosquamatus venom, activates platelet via GPIb. 2004 Toxicon pmid:15501291